New Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...

CPFT experts have launched a new service providing specialist advice and guidance with research to help people living with ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

Researchers have found that repetitive transcranial magnetic stimulation (rTMS) can efficiently reduce the symptoms of ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...